Sponsors (2)
The bill gives drugmakers 180 extra days of exclusivity to encourage investment in rare/COVID-related therapies, but it does so at the cost of higher drug prices and increased spending for patients, hospitals, insurers, and taxpayers in the short term.
Manufacturers of covered orphan drugs gain 180 additional days of market exclusivity, delaying generic/biosimilar competition and increasing manufacturer revenues.
Patients with rare or COVID-19–related conditions may benefit long-term because the extended exclusivity preserves incentives for developers to invest in rare-disease therapies arising from COVID-19 research.
Patients and insurers will face higher drug prices and delayed access to lower-cost generics/biosimilars for an additional 180 days, increasing out-of-pocket costs and insurance spending.
Taxpayers and public payers could face higher government and program spending because extended exclusivity raises overall drug expenditures borne by federal/state programs and indirectly by taxpayers.
Hospitals and health systems will incur higher procurement costs and budget pressure while cheaper alternatives are blocked, potentially straining finances and care delivery.
Based on analysis of 2 sections of legislative text.
Adds a 180‑day extension to specified drug and biologic exclusivity and patent-related approval‑delay periods for qualifying orphan drugs affected by the COVID‑19 emergency.
Introduced February 25, 2026 by Josh S. Gottheimer · Last progress February 25, 2026
Extends certain FDA exclusivity and patent-related approval-delay periods by 180 days for qualifying orphan drugs that were affected by the COVID‑19 emergency. The extension applies to multiple statutory exclusivity periods (including biologics, new drug, generic, pediatric, and orphan exclusivity terms) and to patent-certification/approval-delay periods, takes effect on enactment, and only applies if the exclusivity period has not already expired.